An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria

An Open-Label, Investigator-Initiated, Single-Centre Pilot Study to Determine the Safety and Efficacy of Tofacitinib in Resistant Chronic Spontaneous Urticaria

Background: Chronic spontaneous urticaria (CSU) is a distressing skin condition characterized by the recurrent appearance of itchy hives. A subset of CSU patients remains resistant to conventional treatment with high-dose antihistamines. Tofacitinib, a Janus kinase inhibitor, has shown promise in va...

Cijeli opis

Bibliografski detalji
Glavni autori: Abhishek De, Shrayan Pal, Sushil Singh, Disha Chakroborty, Kiran Godse
Format: Članak
Jezik:English
Izdano: Wolters Kluwer Medknow Publications 2024-08-01
Serija:Indian Journal of Dermatology
Teme:
chronic spontaneous urticaria
jak inhibitor
janus kinase inhibitor
resistant urticaria
tofacitinib
Online pristup:https://journals.lww.com/10.4103/ijd.ijd_1085_23

Internet

https://journals.lww.com/10.4103/ijd.ijd_1085_23

Slični predmeti